Fecal Microbiota Transplantation is a Promising Switch Therapy for Patients with Prior Failure of Infliximab in Crohn's Disease
Background: How to handle patients with anti-tumor necrosis factor (anti-TNF) failure was a common challenge to clinicians in Crohn's disease (CD). The present study is dedicated to clarifying whether fecal microbiota transplantation (FMT) could be a switch therapy for patients with prior failu...
Saved in:
Main Authors: | Qianqian Li (Author), Xiao Ding (Author), Yujie Liu (Author), Cicilia Marcella (Author), Min Dai (Author), Ting Zhang (Author), Jianling Bai (Author), Liyuan Xiang (Author), Quan Wen (Author), Bota Cui (Author), Faming Zhang (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2021-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Rapamycin is Effective for Upper but not for Lower Gastrointestinal Crohn's Disease-Related Stricture: A Pilot Study
by: Min Zhong, et al.
Published: (2021) -
The COVID-19 Vaccination Hesitancy Among the People With Inflammatory Bowel Disease in China: A Questionnaire Study
by: Xia Wu, et al.
Published: (2021) -
HX008: a humanized PD-1 blocking antibody with potent antitumor activity and superior pharmacologic properties
by: Jibin Zhang, et al.
Published: (2020) -
Switch from Infliximab to Infliximab-dyyb for Rheumatology Indications
by: Alexi Spoto, et al.
Published: (2021) -
A case report of drug-induced liver injury due to the infliximab biosimilar CT-P13 on switching from original infliximab in a patient with Crohn's disease
by: Shin Kashima, et al.
Published: (2022)